Latest news

Debiopharm S.A. seeks New Partner to Commercialise Trelstar® (Triptorelin Pamoate) in the US, Canada and Mexico for the Treatment of…

Debiopharm presents results of a first monthly injectable sustained-release fomulation of ZT-1 for Alzheimer´s Disease

Debiopharm and Tulane Cancer Center select Hemenway as the 2003 Mauvernay Research Excellence Scholar

Debiopharm SA starts a Phase II trial for a once daily oral formulation of ZT-1 to treat Alzheimer´s

Debiopharm S.A. and Dyax Corp. granted European Orphan Drug Status for EPI-hNE4 (DX-890) for Cystic Fibrosis Indication

H3 Pharma Inc. announces important step in bringing SANVAR® (vapreotide) to U.S. market

H3 Pharma Inc. Licenses in Sanvar ® (vapreotide) from Debiopharm S.A.

DEBIOPHARM S.A. licenses-in a compound from Genodyssee S.A.

Debiopharm S.A. provides funding to Tulane University